Annexon, Inc.

Annexon, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for inflammatory-related diseases. Its lead product candidate is Tanruprubart, a full-length monoclonal antibody currently in Phase 3 clinical trials for treating Guillain-Barré syndrome. The company also has a portfolio that includes ANX007, an antigen-binding fragment in Phase 3 for geographic atrophy; ANX1502, an oral small molecule inhibitor in Phase 1 for autoimmune indications; and ANX009, a C1q-blocking Fab in Phase 1 for lupus nephritis. Additionally, Annexon has completed Phase 2 trials for Huntington's disease and is conducting a Phase 2a trial for amyotrophic lateral sclerosis.

Annexon, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol ANNX. The company trades in United States Dollars (USD), which is the official currency of the United States where the exchange is based. As a Nasdaq-listed company, Annexon is subject to the reporting and governance requirements of the U.S. Securities and Exchange Commission (SEC).

Annexon, Inc. operates in the Healthcare sector and specifically within the Biotechnology industry. As a biotechnology company, it focuses on using biological processes and living organisms to develop therapeutic drugs. Its clinical-stage pipeline targets inflammatory and autoimmune diseases, with candidates ranging from monoclonal antibodies to small molecule inhibitors. The biotechnology industry is characterized by high research and development costs, lengthy clinical trial processes, and the potential for significant breakthroughs in treating unmet medical needs.

Annexon, Inc. is headquartered in Brisbane, California, United States. The company was incorporated in 2011 and primarily serves the U.S. market, as indicated by its listing on the Nasdaq and its focus on clinical trials conducted in the United States. While its therapies target global diseases such as Guillain-Barré syndrome, geographic atrophy, and lupus nephritis, the company's operations and regulatory filings are centered in the U.S. As a clinical-stage biopharmaceutical company, it does not yet have approved products on the market, so its current activities are focused on research, development, and clinical trials.

Annexon's pipeline includes several investigational therapies targeting inflammatory and autoimmune conditions. The most advanced is Tanruprubart, a full-length monoclonal antibody in Phase 3 trials for Guillain-Barré syndrome. Another key candidate is ANX007, an antigen-binding fragment (Fab) in Phase 3 for geographic atrophy, a leading cause of blindness. For autoimmune indications, ANX1502 is an oral small molecule inhibitor in Phase 1, and ANX009 is a C1q-blocking Fab in Phase 1 for lupus nephritis. Additionally, Annexon has completed a Phase 2 trial for Huntington's disease and is conducting a Phase 2a trial for amyotrophic lateral sclerosis (ALS). These candidates represent the company's focus on complement-mediated inflammatory diseases.